Drug Combination Details
| General Information of the Combination (ID: C05284) | |||||
|---|---|---|---|---|---|
| Name | Gingerol NP Info | + | Doxorubicin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Hepatocellular carcinoma
[ICD-11: 2C12]
|
Investigative | [1] | ||
|
Breast cancer
[ICD-11: 2C60]
|
Investigative | [2] | |||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | CDK6 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Phosphorylation | H2AFX | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | 4T1Br4 | Breast cancer | Rattus norvegicus | |||
| MDA-MB-231 HMTL.6 | Breast cancer | Homo sapiens | ||||
| In-vivo Model | For a xenograft model, 1*106 human MDA-MB-231 HMTL.6 cells were injected into the inguinal mammary fat pad of Balb/c congenic athymic nude mice. | |||||
| Experimental
Result(s) |
[10]-Gingerol improves doxorubicin anticancer activity and decreases its side effects in triple negative breast cancer models. | |||||
| β. Decreasing Adverse Drug Reaction by This Combination | ||||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | 4T1Br4 | Breast cancer | Rattus norvegicus | |||
| MDA-MB-231 HMTL.6 | Breast cancer | Homo sapiens | ||||
| In-vivo Model | For a xenograft model, 1*106 human MDA-MB-231 HMTL.6 cells were injected into the inguinal mammary fat pad of Balb/c congenic athymic nude mice. | |||||
| Experimental
Result(s) |
[10]-Gingerol improves doxorubicin anticancer activity and decreases its side effects in triple negative breast cancer models. | |||||
| Experiment 2 Reporting the Effect of This Combination | [1] | |||||
| Biological
Regulation |
Induction | Cell cycle arrest in G2/M phase | ||||
| Blockade | Exaggerated vasoconstriction and impaired vascular relaxation induced by doxorubicin | |||||
| In-vitro Model | Hep-G2 | CVCL_0027 | Hepatocellular carcinoma | Homo sapiens | ||
| Huh-7 | CVCL_0336 | Adult hepatocellular carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Gingerol protected from DOX-induced vascular damage and synergized the cytotoxic effects of DOX against liver cancer cells without influencing the cellular pharmacokinetics. | |||||
